PD-L1 expression tends to correlate with greater treatment response, but is not a perfect biomarker because bladder cancer with low or no PD-L1 expression has robust response efficacy and better tolerability than traditional chemotherapy13. This evidence concerns the gene CD274 and urinary bladder carcinoma.